Champions Oncology, Inc.
CSBRHealthcare|Biotechnology|US
$4.79
+0.03 (+0.63%)
DCF Value
$4.14
Tangible Book / Share
$0.30
Cash / Share
$0.31
Clinical Trials (3)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT02752932 TumorGraft- Guided Therapy for Improved Outcomes in Head and Neck Squamous Cell Cancer- A Feasibility Study | Head and Neck Squamous Cell Carcinoma | N/A | Completed | 41 | Open-label | — |
| NCT02720796 Patient-Derived Xenograft (PDX) Modeling in Adult Patients With Metastatic or Recurrent Sarcoma | Sarcoma | N/A | Terminated | 17 | Open-label | — |
| NCT02247037 Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer | Triple Negative Breast Cancer | Completed | 68 | — | — |